Sarcoma Drugs Market: Global Industry Analysis and Forecast (2024-2030)

Sarcoma Drugs Market size was valued at USD 1148.58 Mn. in 2023 and the total revenue is expected to grow by 23% from 2024 to 2030, reaching nearly USD 4892.15 Mn.

Sarcoma Drugs Market Overview:

Sarcoma is a type of cancer that can appear anywhere in the body. Growing patient assistance programs, new product launches by large pharmaceutical companies, and these companies' increased focus on R&D are driving the development of novel and advanced therapeutics in the sarcoma drugs market. Over recent years prescription drug prices, have been rapidly growing, sometimes by double digits. This has resulted in an increase in overall healthcare spending, making drugs increasingly unattainable for those with limited financial resources. The growing incidence and prevalence of various types of cancers, rising cases of soft tissue sarcoma, increased R&D activities on drugs and other therapies, and the expiration of branded drug patents are some of the factors are expected to drive the growth of the sarcoma drugs market during the forecast period. However, stringent regulatory guidelines, adverse treatment side effects, and high radiotherapy and chemotherapy costs impede the growth of the sarcoma treatment market during the forecast period. Sarcomas account for less than 1% of all adult cancers. Though sarcomas are a diverse group with over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcomas. Every year, approximately 12,000 patients in the United States and 28,000 in Europe are diagnosed with STS. For more than 40 years, the standard treatment for localized sarcomas was surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. Despite complete surgical resection, approximately 50.0% of patients with intermediate or high-grade sarcoma develop metastatic disease. The introduction of targeted therapy has transformed the sarcoma treatment paradigm. Throughout the forecast period, targeted therapies and pipeline breakthroughs will continue to play a critical role in market growth.Sarcoma Drugs MarketTo know about the Research Methodology :- Request Free Sample Report

Sarcoma Drugs Market Dynamics:

Growing use of immunotherapy for the treatment of sarcoma Immunotherapy is a treatment that employs specific components of a person's immune system to combat diseases and is expected to drive such as cancer. This can be accomplished in two ways: 1. Stimulating or boosting a patient’s immune system's natural defenses so that it works harder or smarter to find and attack cancer cells. 2. Creating substances in a lab that are similar to immune system components and using them to help restore or improve how a patient’s immune system finds and attacks cancer cells. Immunotherapy has become an important part of treating certain types of cancer in recent years. New immunotherapy treatments are being tested and approved at a rapid pace, as are new ways of working with the immune system. Immunotherapy works better for various cancers than others. It is used alone for some of these cancers, but it appears to work better when combined with other types of treatment for others. These aspects are expected to boost the sarcoma drugs market growth and is expected to do the same during the forecast period. Sarcoma Drugs Market 3Increasing Cancer Prevalence to support Sarcoma Drugs Market Growth Cancer has become the second leading cause of death worldwide, trailing only cardiovascular disease. This phenomenon is caused by environmental factors such as tobacco use, changing dietary patterns, urbanization, and an extended post-reproductive lifespan. According to the World Health Organization (WHO), cancer is a growing burden, with the number of new cancer cases expected to rise from 18.1 million in 2018 to 29.4 million by 2040. As a result, the rising prevalence of cancer is expected to drive demand for the global oncology cancer drugs market during the forecast period. Furthermore, rising public awareness of cancer is expected to benefit the sarcoma drugs market in the forecast years. According to the Kaiser Family Foundation, more than 47 million Americans lacked health insurance in 2020, and millions more were underinsured, with eight out of ten uninsured people coming from salaried families. One out of every ten people with health insurance who are 65 or younger, and one out of every three people over 65, did not have prescription treatment coverage. Patient Assistance Programs (PAPs) were created in an effort to assist patients who do not have health insurance or prescription drug coverage in obtaining the medication they require. Pharmaceutical companies typically provide these programs, which provide free or low-cost prescription drugs to patients suffering from serious diseases. Many states provide medication assistance programs that vary by state and cater to the elderly, disabled, or those in financial need. Some of the programs are tailored to specific conditions, such as cancer. Pharmaceutical companies donate drugs to foundations, which then distribute them to qualifying patients. Several large pharmaceutical companies, including Pfizer and Eli Lilly, have also launched similar programs to assist uninsured patients suffering from chronic diseases. As a result of the high number of PAPs, uninsured cancer patients can now receive cancer therapies, which is expected to boost the sarcoma drugs market growth. Possession of a Strong Drug Pipeline to Fuel Sarcoma Drugs Market Growth Opportunities The rate of change in cancer treatment is quickening. The research and development pipeline is producing a slew of novel treatments that are frequently combined with other new or existing medications. Many pharmaceutical companies are investing in novel drug research for cancer treatment. Pfizer, for example, acquired Array BioPharma in June 2019 with the goal of expanding its oncology presence and pipeline, beginning with an approved combination therapy for melanoma that is now in a phase 3 trial for a type of metastatic colorectal cancer. This, combined with an increasing preference for biosimilar and biologics entering the market, is expected to boost the sarcoma drugs market growth. Sarcoma Drugs Market 2

Sarcoma Drugs Market Restraints

Adverse drug effects, stringent regulations, and patent expiration Chemotherapy drugs kill cancer cells while also harming normal body cells. This has a variety of side effects for the patients. The most common side effects are bone marrow suppression, gastrointestinal disorders, neuropathies, hair loss, fatigue, and skin disorders. As a result, the adverse effects associated with oncology drugs are having a negative impact on the market's growth. In addition, stringent government regulations, high drug costs, and patent expiration are some of the other factors hampering the sarcoma drugs market growth during the forecast period. Sarcoma Drugs Market Opportunity Increasing R&D Investment to Promote the Adoption of Advanced Drug Therapies Cancer treatment aims to cure the disease, prolong survival, and improve quality of life. Immune cells are critical in tumor progression. Stimulating immune responses to tumors is thus an appealing therapeutic and preventive strategy. Top market players are thus investing in immunotherapy research and development to treat various cancers. In March 2019, for example, FUJIFILM Corporation and the National Cancer Center Japan announced the launch of a joint research project for new cancer immunotherapy using a liposome formulation. Immunotherapy is more widely used in the market due to its success in terms of efficient treatment, which results in better patient outcomes. This, in turn, contributes to market growth.

Sarcoma Drugs Market Segment Analysis:

Based on Treatment Type, the Chemotherapy segment dominated the sarcoma drugs market with 55% and is expected to do the same during the forecast period. Chemotherapy is the most commonly used type of therapeutic to stop or slow the growth of cancer cells. Surgery and radiation therapy remove, kill, or damage cancer cells in a specific area, whereas chemotherapy works throughout the body. This means that chemotherapy has the ability to destroy and damage cancer cells that have spread to other parts of the body, away from the original tumor. Additionally, according to a study on the trends in receiving chemotherapy for advanced cancer patients, the proportion of patients receiving chemotherapy increased sequentially at the end of life. With the introduction of targeted therapies, the landscape of sarcoma treatment has shifted dramatically in recent years. Gleevec, one of the first molecular targeted drugs approved for solid tumors, was approved as first-line therapy for GIST, a major sarcoma subtype, in 2002, changing the treatment paradigm for GIST. Following Gleevec, other tyrosine kinase inhibitors (TKIs) for GISTs, such as Sutent and Stivarga, and Votrient for non-GIST soft tissue sarcomas, were approved. In addition to TKIs, Lartruvo, a monoclonal antibody that targets platelet-derived growth factor receptor (PDGFR), has been shown to improve overall survival in STS patients and was approved as a breakthrough therapy in the United States in 2016. New drugs for bone sarcomas are limited to Xgeva, a RANKL (receptor activator of nuclear factor B ligand) inhibitor.Sarcoma Drugs Market1Based on the Application, Hospital pharmacies dominated the sarcoma drug market. The market is divided into two distribution channels: hospital pharmacies and retail pharmacies. as well as retail pharmacies and online pharmacies. The hospital pharmacy market is expected to be dominant throughout the forecast period. The rising number of prescriptions and the increased use of medications in hospitals as a result of more frequent diagnoses at these facilities is the reasons for this segment's dominance Furthermore, the online pharmacies market is expected to grow. Furthermore, the online pharmacy market is expected to grow. Due to its increasing popularity, it grows at a CAGR of 15% during the forecast period to its comfort and convenience

Sarcoma Drugs Market Regional Insights:

North America has the largest market share. According to the American Cancer Society, approximately 12,750 new soft tissue sarcomas will be diagnosed in the United States, with 7,240 men and 5,510 women affected. In terms of mortality, this society predicts that approximately 5,270 Americans will die from Sarcoma in 2019. Every year, approximately 40 people per million in the United States are diagnosed with Sarcoma. Companies are focusing on developing drugs that will alleviate the symptoms of Sarcoma in order to combat this cancer. Because of people's increasing acceptance of novel therapeutics and companies' increasing focus on establishing a strong presence in the United States, the market for sarcoma drugs is expected to grow rapidly in this region during the forecast period.

Sarcoma Drugs Market Scope: Inquiry Before Buying

Sarcoma Drugs Market
Report Coverage Details
Base Year: 2023 Forecast Period: 2024-2030
Historical Data: 2018 to 2023 Market Size in 2023: US $ 1148.58 Mn.
Forecast Period 2024 to 2030 CAGR: 23% Market Size in 2030: US $ 4892.15 Mn.
Segments Covered: by Treatment Type Chemotherapy Targeted Therapy
by Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
by Disease Indication Malignant bone tumors Soft tissue sarcoma Type Dermatofibro sarcoma Leiomyosarcoma Synovial cell sarcoma Rhabdomyo sarcoma Others

Sarcoma Drugs Market, by Region

 North America (United States, Canada and Mexico)  Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)  Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)  Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)  South America (Brazil, Argentina Rest of South America)

Sarcoma Drugs Market, Key Players are

1. Eisai Co., Ltd. 2. Johnson and Johnson 3. Bayer AG 4. Pfizer Inc. 5. Fresenius Kabi AG 6. Novartis AG 7. Epizyme, Inc. 8. Eli Lilly and Company 9. Bristol-Myers Squibb Company 10. Merck & Co., Inc., 11. F.Hoffmann-La Roche AG, 12. Daiichi Sankyo Company Limited, 13. AgonOX, Inc., Frequently Asked Questions: 1] What is the most effective treatment for sarcoma? Ans. Surgery is a necessary component of the treatment for all soft tissue sarcomas because it is the only way to eradicate a soft tissue sarcoma. 2] Are there any new treatments for sarcoma? Ans. Pazopanib inhibits several cell enzymes known as tyrosine kinases, which are necessary for cell growth and survival. It may be used to treat certain advanced soft tissue sarcomas that have not responded to chemotherapy. 3] What is the best treatment for soft tissue sarcoma? Ans. Soft tissue sarcoma is commonly treated with surgery. Cancer and some healthy tissue surrounding it are usually removed during surgery. When soft tissue sarcoma affects the arms and legs, radiation and chemotherapy to shrink the tumor may be considered to avoid amputation. 4] What treatment is used for sarcomas? Ans. Sarcoma treatment may include chemotherapy, radiation therapy, and surgery in general. For example, osteosarcoma treatment may include nine weeks of chemotherapy, surgery to remove the tumor and rebuild the bone, and another five months of chemotherapy. 5] What are 3 different types of sarcomas? Ans. The Most Common Sarcoma Subtypes : Osteosarcoma - A cancer that develops in the cells that form bones. Dermatofibrosarcoma protuberans (DFSP) - A skin tumor. Fibrosarcoma (fibroblastic sarcoma) - A type of cancer that develops in fibrous tissue.
1. Global Sarcoma Drugs Market: Research Methodology 2. Global Sarcoma Drugs Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Sarcoma Drugs Market 2.2. Summary 2.2.1. Key Findings 2.2.2. Recommendations for Investors 2.2.3. Recommendations for Market Leaders 2.2.4. Recommendations for New Market Entry 3. Global Sarcoma Drugs Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • South America 3.12 COVID-19 Impact 4. Global Sarcoma Drugs Market Segmentation 4.1 Global Sarcoma Drugs Market, by Treatment Type (2023-2030) • Chemotherapy • Targeted Therapy 4.2 Global Sarcoma Drugs Market, by Distribution Channel (2023-2030) • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Others 4.3 Global Sarcoma Drugs Market, by Disease Indication (2023-2030) • Malignant bone tumors • Soft tissue sarcoma Type • Dermatofibro sarcoma • Leiomyosarcoma • Synovial cell sarcoma • Rhabdomyo sarcoma • Others 5. North America Sarcoma Drugs Market(2023-2030) 5.1 North America Sarcoma Drugs Market, by Treatment Type (2023-2030) • Chemotherapy • Targeted Therapy 5.2 North America Sarcoma Drugs Market, by Distribution Channel (2023-2030) • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies • Others 5.3 North America Sarcoma Drugs Market, by Disease Indication (2023-2030) • Malignant bone tumors • Soft tissue sarcoma Type • Dermatofibro sarcoma • Leiomyosarcoma • Synovial cell sarcoma • Rhabdomyo sarcoma • Others 5.4 North America Sarcoma Drugs Market, by Country (2023-2030) • United States • Canada • Mexico 6. Europe Sarcoma Drugs Market (2023-2030) 6.1. European Sarcoma Drugs Market, by Treatment Type (2023-2030) 6.2. European Sarcoma Drugs Market, by Distribution Channel (2023-2030) 6.3. European Sarcoma Drugs Market, by Disease Indication (2023-2030) 6.4. European Sarcoma Drugs Market, by Country (2023-2030) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 7. Asia Pacific Sarcoma Drugs Market (2023-2030) 7.1. Asia Pacific Sarcoma Drugs Market, by Treatment Type (2023-2030) 7.2. Asia Pacific Sarcoma Drugs Market, by Distribution Channel (2023-2030) 7.3. Asia Pacific Sarcoma Drugs Market, by Disease Indication (2023-2030) 7.4. Asia Pacific Sarcoma Drugs Market, by Country (2023-2030) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 8. Middle East and Africa Sarcoma Drugs Market (2023-2030) 8.1 Middle East and Africa Sarcoma Drugs Market, by Treatment Type (2023-2030) 8.2. Middle East and Africa Sarcoma Drugs Market, by Distribution Channel (2023-2030) 8.3. Middle East and Africa Sarcoma Drugs Market, by Disease Indication (2023-2030) 8.4. Middle East and Africa Sarcoma Drugs Market, by Country (2023-2030) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 9. South America Sarcoma Drugs Market (2023-2030) 9.1. South America Sarcoma Drugs Market, by Treatment Type (2023-2030) 9.2. South America Sarcoma Drugs Market, by Distribution Channel (2023-2030) 9.3. South America Sarcoma Drugs Market, by Disease Indication (2023-2030) 9.4 South America Sarcoma Drugs Market, by Country (2023-2030) • Brazil • Argentina • Rest Of South America 10. Company Profile: Key players 10.1 Eisai Co., Ltd. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 Johnson and Johnson 10.3 Bayer AG 10.4 Pfizer Inc. 10.5 Fresenius Kabi AG 10.6 Novartis AG 10.7 Epizyme, Inc. 10.8 Eli Lilly and Company 10.9 Bristol-Myers Squibb Company 10.10 Merck & Co., Inc., 10.11 F.Hoffmann-La Roche AG, 10.12 Daiichi Sankyo Company Limited, 10.13 AgonOX, Inc.,